Dehydrojuncusol, a natural phenanthrene compound extracted from Juncus maritimus, is a new inhibitor of hepatitis C virus RNA replication
Marie-Emmanuelle Sahuc
Ramla Sahli
Céline Rivière
Véronique Pène
Muriel Lavie
Alexandre Vandeputte
Priscille Brodin
Arielle R. Rosenberg
Jean Dubuisson
Riadh Ksouri
Yves Rouillé
Sevser Sahpaz
Karin Séron
J.-H. James Ou
Journal of virology, 2019-5
Yves Rouillé
Rouillé Yves
ORCID: 0000-0003-0788-9271
Identification of class II ADP-ribosylation factors as cellular factors required for hepatitis C virus replication
10.1111/cmi.12572
Role of the prohormone convertase PC2 in the processing of proglucagon to glucagon
10.1016/s0014-5793(97)00892-2
Role of the prohormone convertase PC3 in the processing of proglucagon to glucagon-like peptide 1
10.1074/jbc.272.52.32810
Internal cleavage of the inhibitory 7B2 carboxyl-terminal peptide by PC2: A potential mechanism for its inactivation
10.1073/pnas.93.10.4919
DISTINCT HYDRO-OSMOTIC RECEPTORS FOR THE NEUROHYPOPHYSEAL PEPTIDES VASOTOCIN AND HYDRINS IN THE FROG RANA-ESCULENTA
10.1016/0143-4179(95)90039-x
HYPERPROINSULINAEMIA IN OBESE FAT/FAT MICE ASSOCIATED WITH A CARBOXYPEPTIDASE-E MUTATION WHICH REDUCES ENZYME-ACTIVITY
10.1038/ng0695-135
PROTEOLYTIC PROCESSING MECHANISMS IN THE BIOSYNTHESIS OF NEUROENDOCRINE PEPTIDES - THE SUBTILISIN-LIKE PROPROTEIN CONVERTASES
10.1006/frne.1995.1012
ACTION OF NEUROHYPOPHYSEAL GRANULE LYS-ARG ENDOPEPTIDASE ON SYNTHETIC POLYPEPTIDES COMPRISING THE PROCESSING SEQUENCE OF PROVASOPRESSIN-NEUROPHYSIN
10.1007/bf01200246
PROGLUCAGON IS PROCESSED TO GLUCAGON BY PROHORMONE CONVERTASE PC2 IN ALPHA-TC1-6 CELLS
10.1073/pnas.91.8.3242
SPECIAL EVOLUTION OF NEUROHYPOPHYSEAL HORMONES IN CARTILAGINOUS FISHES - ASVATOCIN AND PHASVATOCIN, 2 OXYTOCIN-LIKE PEPTIDES ISOLATED FROM THE SPOTTED DOGFISH (SCYLIORHINUS-CANICULUS)
10.1073/pnas.91.23.11266
A NEUROSECRETORY GRANULE LYS-ARG CA2+-DEPENDENT ENDOPEPTIDASE PUTATIVELY INVOLVED IN PROOXYTOCIN AND PROVASOPRESSIN PROCESSING
10.1016/0143-4179(92)90050-7
EVIDENCE FOR DISTINCT DIBASIC PROCESSING ENDOPEPTIDASES WITH LYS-ARG AND ARG-ARG SPECIFICITIES IN NEUROHYPOPHYSEAL SECRETORY GRANULES
10.1016/0006-291x(92)91618-z
PROCESSING ENDOPEPTIDASE DEFICIENCY IN NEUROHYPOPHYSEAL SECRETORY GRANULES OF THE DIABETES-INSIPIDUS (BRATTLEBORO) RAT
10.1007/bf01122032
HETEROLOGUE CONVERSION OF AMPHIBIAN HYDRIN-2 INTO VASOTOCIN THROUGH BOVINE GRANULE ALPHA-AMIDATING ENZYME
10.1111/j.1365-2826.1991.tb00233.x
NEUROHYPOPHYSEAL HORMONES AS MOLECULAR EVOLUTIONARY TRACERS - INVESTIGATIONS ON THE STURGEONS ACIPENSER-STELLATUS AND ACIPENSER-GULDENSTADTI
10.1016/0305-0491(91)90280-q
EVOLUTIONARY SPECIFICITY OF HYDRINS, NEW HYDROOSMOTIC NEUROPEPTIDES - OCCURRENCE OF HYDRIN-2 (VASOTOCINYL-GLY) IN THE TOAD BUFO-MARINUS BUT NOT IN THE VIPER VIPERA-ASPIS
10.1016/0014-5793(90)80783-f
IDENTIFICATION OF 2 TYPES OF NEUROPHYSINS IN XENOPUS-LAEVIS NEUROINTERMEDIATE PITUITARY HOMOLOGOUS TO MAMMALIAN MSEL-NEUROPHYSIN AND VLDV-NEUROPHYSIN
10.1016/0143-4179(90)90142-l
OCCURRENCE OF HYDRIN-2 (VASOTOCINYL-GLY), A NEW HYDROOSMOTIC NEUROHYPOPHYSEAL PEPTIDE, IN SECRETORY GRANULES ISOLATED FROM THE FROG (RANA-ESCULENTA) NEUROINTERMEDIATE PITUITARY
10.1159/000125343
HYDRINS, HYDROOSMOTIC NEUROHYPOPHYSEAL PEPTIDES - OSMOREGULATORY ADAPTATION IN AMPHIBIANS THROUGH VASOTOCIN PRECURSOR PROCESSING
10.1073/pnas.86.14.5272
ISOLATION OF NEUROSECRETORY GRANULES CONTAINING VASOTOCIN, MESOTOCIN, MSEL-NEUROPHYSINS AND VLDV-NEUROPHYSINS FROM GOOSE NEUROHYPOPHYSIS
10.1016/0143-4179(89)90090-5
PARTICULAR PROCESSING OF PRO-OPIOMELANOCORTIN IN XENOPUS-LAEVIS INTERMEDIATE PITUITARY - SEQUENCING OF ALPHA-MELANOCYTE-STIMULATING, AND BETA-MELANOCYTE-STIMULATING HORMONES
10.1016/0014-5793(89)80224-8
DUAL DUPLICATION OF NEUROHYPOPHYSEAL HORMONES IN AN AUSTRALIAN MARSUPIAL - MESOTOCIN, OXYTOCIN, LYSINE VASOPRESSIN AND ARGININE VASOPRESSIN IN A SINGLE GLAND OF THE NORTHERN BANDICOOT (ISOODON-MACROURUS)
10.1016/0006-291x(88)90691-2
ISOLATION OF NEUROSECRETORY GRANULES CONTAINING VASOPRESSIN AND MSEL-NEUROPHYSIN FROM GUINEA-PIG NEUROINTERMEDIATE PITUITARY
10.1016/0143-4179(88)90025-x
NEUROHYPOPHYSEAL HORMONES OF THE 1-MONTH-OLD BOVINE FETUS - ABSENCE OF VASOTOCIN DURING MAMMAL DEVELOPMENT
10.1016/0014-5793(88)80113-3
THE DISTRIBUTION OF LYSINE VASOPRESSIN (LYSIPRESSIN) IN PLACENTAL MAMMALS - A REINVESTIGATION OF THE HIPPOPOTAMIDAE (HIPPOPOTAMUS-AMPHIBIUS) AND TAYASSUIDAE (TAYASSU-ANGULATUS) FAMILIES
10.1016/0016-6480(88)90277-8
EVOLUTION OF MARSUPIALS TRACED BY THEIR NEUROHYPOPHYSEAL HORMONES - MICROIDENTIFICATION OF MESOTOCIN AND ARGININE VASOPRESSIN IN 2 AUSTRALIAN FAMILIES, DASYURIDAE AND PHASCOLARCTIDAE
10.1016/0016-6480(87)90195-x
GUINEA-PIG NEUROHYPOPHYSEAL HORMONES - PECULIAR PROCESSING OF THE 3-DOMAIN VASOPRESSIN PRECURSOR
10.1016/0014-5793(87)81294-2
Hexim1, a Novel Regulator of Leptin Function, Modulates Obesity and Glucose Disposal
10.1210/me.2015-1211
Identification of a New Benzimidazole Derivative as an Antiviral against Hepatitis C Virus
10.1128/jvi.00404-16
Khaya grandifoliola C.DC: a potential source of active ingredients against hepatitis C virus in vitro
10.1007/s00705-016-2771-5
Morphology and Molecular Composition of Purified Bovine Viral Diarrhea Virus Envelope
10.1371/journal.ppat.1005476
Recent advances in human viruses imaging studies
10.1002/jobm.201500575
New Insights into the Understanding of Hepatitis C Virus Entry and Cell-to-Cell Transmission by Using the Ionophore Monensin A
10.1128/jvi.00192-15
Plant extracts from Cameroonian medicinal plants strongly inhibit hepatitis C virus infection in vitro
10.3389/fmicb.2015.00438
Polyphenols Inhibit Hepatitis C Virus Entry by a New Mechanism of Action
10.1128/jvi.01473-15
Regulation of core expression during the hepatitis C virus life cycle
10.1099/vir.0.070433-0
FTO contributes to hepatic metabolism regulation through regulation of leptin action and STAT3 signalling in liver
10.1186/1478-811x-12-4
Hepatitis C Virus Capsid Protein and Intracellular Lipids Interplay and Its Association With Hepatic Steatosis
10.5812/hepatmon.17812
Potent antiviral activity of Solanum rantonnetii and the isolated compounds against hepatitis C virus in vitro
10.1016/j.jff.2014.09.022
Structure-activity studies of (-)-epigallocatechin gallate derivatives as HCV entry inhibitors
10.1016/j.bmcl.2014.07.051
Hepatitis C Virus Replication and Golgi Function in Brefeldin A-Resistant Hepatoma-Derived Cells
10.1371/journal.pone.0074491
(-)-Epigallocatechin-3-gallate is a new inhibitor of hepatitis C virus entry
10.1002/hep.24803
Hepatitis C Virus and Natural Compounds: A New Antiviral Approach?
10.3390/v4102197
Role of low-density lipoprotein receptor in the hepatitis C virus life cycle
10.1002/hep.25501
Endospanins Regulate a Postinternalization Step of the Leptin Receptor Endocytic Pathway
10.1074/jbc.M111.224857
HCV replication and assembly: a play in one act
10.2217/fvl.11.69
Hepatitis C Virus Assembly Imaging
10.3390/v3112238
Hepatocyte-derived cultured cells with unusual cytoplasmic keratin-rich spheroid bodies
10.1016/j.yexcr.2011.08.018
NS2 Protein of Hepatitis C Virus Interacts with Structural and Non-Structural Proteins towards Virus Assembly
10.1371/journal.ppat.1001278
Identification of a dominant endoplasmic reticulum-retention signal in yellow fever virus pre-membrane protein
10.1099/vir.0.015339-0
Identification of Basic Amino Acids at the N-Terminal End of the Core Protein That Are Crucial for Hepatitis C Virus Infectivity
10.1128/jvi.01393-10
Identification of GBF1 as a Cellular Factor Required for Hepatitis C Virus RNA Replication
10.1128/jvi.01190-09
LEPROT and LEPROTL1 cooperatively decrease hepatic growth hormone action in mice
10.1172/jci34997
Robust production of infectious viral particles in Huh-7 cells by introducing mutations in hepatitis C virus structural proteins
10.1099/vir.0.82872-0
Silencing of OB-RGRP in mouse hypothalamic arcuate nucleus increases leptin receptor signaling and prevents diet-induced obesity
10.1073/pnas.0706671104
Hepatitis C virus entry depends on clathrin-mediated endocytosis
10.1128/jvi.00024-06
Subcellular localization of hepatitis C virus structural proteins in a cell culture system that efficiently replicates the virus
10.1128/jvi.80.6.2832-2841.2006
Ubiquitylation of leptin receptor OB-Ra regulates its clathrin-mediated endocytosis
10.1038/sj.emboj.7600989
Bovine viral diarrhea virus entry is dependent on clathrin-mediated endocytosis
10.1128/jvi.79.16.10826-10829.2005
Interactions between virus proteins and host cell membranes during the viral life cycle
10.1016/s0074-7696(05)45006-8
Significance of prohormone convertase 2, PC2, mediated initial cleavage at the proglucagon interdomain site, Lys70-Arg71, to generate glucagon
10.1210/en.2004-1118
Low levels of expression of leptin receptor at the cell surface result from constitutive endocytosis and intracellular retention in the biosynthetic pathway
10.1074/jbc.M400508200
The transmembrane domains of the prM and E proteins of yellow fever virus are endoplasmic reticulum localization signals
10.1128/jvi.78.22.12591-12602.2004
Visualization of TGN to endosome trafficking through fluorescently labeled MPR and AP-1 in living cells
10.1091/mbc.E02-06-0338
Dynamic processing of neuropeptides - Sequential conformation shaping of neurohypophysial preprohormones during intraneuronal secretory transport
10.1385/jmn:18:3:223
Yeast Vps55p, a functional homolog of human obesity receptor gene-related protein, is involved in late endosome to vacuole trafficking
10.1091/mbc.01-12-0597
Targeting of lysosomal proteins
10.1006/scdb.2000.0168
Unique evolution of neurohypophysial hormones in cartilaginous fishes: Possible implications for urea-based osmoregulation
10.1002/(sici)1097-010x(19991001)284:5<475::aid-jez2>3.0.co;2-9
Adaptive evolution of water homeostasis regulation in amphibians: Vasotocin and hydrins
10.1016/s0248-4900(97)83380-1
Defective prohormone processing and altered pancreatic islet morphology in mice lacking active SPC2
10.1073/pnas.94.13.6646
Molecular evolution of neurohypophysial hormones in relation to osmoregulation: the two fish options
10.1023/a:1007720909113
Identification of GBF1 as a cellular factor required for hepatitis E virus RNA replication
10.1111/cmi.12804
Entry and release of hepatitis C virus in polarized human hepatocytes.
10.1128/jvi.00478-17
An ecological approach to discover new bioactive extracts and products: the case of extremophile plants.
10.1111/jphp.12728
Endospanin1 affects oppositely body weight regulation and glucose homeostasis by differentially regulating central leptin signaling.
10.1016/j.molmet.2016.10.009
Identification of Novel Functions for Hepatitis C Virus Envelope Glycoprotein E1 in Virus Entry and Assembly.
10.1128/jvi.00048-17
Novel replicons and trans-encapsidation systems for Hepatitis C Virus proteins live imaging and virus-host interaction proteomics.
10.1016/j.jviromet.2017.04.009
Hepatitis C virus life cycle and lipid metabolism.
10.3390/biology3040892
Endospanin-2 enhances skeletal muscle energy metabolism and running endurance capacity
10.1172/jci.insight.98081
Identification of Piperazinylbenzenesulfonamides as New Inhibitors of Claudin-1 Trafficking and Hepatitis C Virus Entry
10.1128/jvi.01982-17
Investigation of the role of GBF1 in the replication of positive-sense single-stranded RNA viruses
10.1099/jgv.0.001099
Functional and Physical Interaction between the Arf Activator GBF1 and Hepatitis C Virus NS3 Protein
10.1128/JVI.01459-18
QuantIF: An ImageJ Macro to Automatically Determine the Percentage of Infected Cells after Immunofluorescence
10.3390/v11020165
Comparative Analysis of Hepatitis C Virus NS5A Dynamics and Localization in Assembly-Deficient Mutants
10.3390/pathogens10020172
Bidirectional genome-wide CRISPR screens reveal host factors regulating SARS-CoV-2, MERS-CoV and seasonal coronaviruses
10.1101/2021.05.19.444823
The C-terminal domain of the MERS coronavirus M protein contains a trans-Golgi network localization signal.
10.1074/jbc.ra119.008964
Ultrastructural modifications induced by SARS-CoV-2 in Vero cells: a kinetic analysis of viral factory formation, viral particle morphogenesis and virion release.
10.1007/s00018-020-03745-y
Dehydrojuncusol, a Natural Phenanthrene Compound Extracted from Juncus maritimus, Is a New Inhibitor of Hepatitis C Virus RNA Replication.
10.1128/jvi.02009-18
Theaflavins, polyphenols of black tea, inhibit entry of hepatitis C virus in cell culture.
10.1371/journal.pone.0198226
Large scale screening discovers clofoctol as an inhibitor of SARS-CoV-2 replication that reduces COVID-19-like pathology
10.1101/2021.06.30.450483
Secretory Vesicles Are the Principal Means of SARS-CoV-2 Egress
10.3390/cells10082047
Karin Seron
Seron Karin
ORCID: 0000-0002-9667-133X
Identification of class II ADP-ribosylation factors as cellular factors required for hepatitis C virus replication
10.1111/cmi.12572
Khaya grandifoliola C.DC: a potential source of active ingredients against hepatitis C virus in vitro
10.1007/s00705-016-2771-5
Characterization of Hepatitis C Virus Interaction with Heparan Sulfate Proteoglycans
10.1128/jvi.03647-14
Claudin-6 and Occludin Natural Variants Found in a Patient Highly Exposed but Not Infected with Hepatitis C Virus (HCV) Do Not Confer HCV Resistance In Vitro
10.1371/journal.pone.0142539
Plant extracts from Cameroonian medicinal plants strongly inhibit hepatitis C virus infection in vitro
10.3389/fmicb.2015.00438
Polyphenols Inhibit Hepatitis C Virus Entry by a New Mechanism of Action
10.1128/jvi.01473-15
Identification of Conserved Residues in Hepatitis C Virus Envelope Glycoprotein E2 That Modulate Virus Dependence on CD81 and SRB1 Entry Factors
10.1128/jvi.01402-14
Potent antiviral activity of Solanum rantonnetii and the isolated compounds against hepatitis C virus in vitro
10.1016/j.jff.2014.09.022
Structure-activity studies of (-)-epigallocatechin gallate derivatives as HCV entry inhibitors
10.1016/j.bmcl.2014.07.051
(-)-Epigallocatechin-3-gallate is a new inhibitor of hepatitis C virus entry
10.1002/hep.24803
Hepatitis C Virus and Natural Compounds: A New Antiviral Approach?
10.3390/v4102197
Endospanins Regulate a Postinternalization Step of the Leptin Receptor Endocytic Pathway
10.1074/jbc.M111.224857
Identification of a dominant endoplasmic reticulum-retention signal in yellow fever virus pre-membrane protein
10.1099/vir.0.015339-0
Silencing of OB-RGRP in mouse hypothalamic arcuate nucleus increases leptin receptor signaling and prevents diet-induced obesity
10.1073/pnas.0706671104
ACDC/adiponectin polymorphisms are associated with severe childhood and adult obesity
10.2337/diabetes.55.02.06.db05-0971
Distinct impaired regulation of SOCS3 and long and short isoforms of the leptin receptor in visceral and subcutaneous fat of lean and obese women
10.1016/j.bbrc.2006.07.068
Genetic study of the CD36 gene In a French diabetic population
10.1016/s1262-3636(07)70143-x
GAD2 on chromosome 10p12 is a candidate gene for human obesity
10.1371/journal.pbio.0000068
Molecular cloning, functional complementation in Saccharomyces cerevisiae and enzymatic properties of phosphatidylinositol synthase from the protozoan parasite Toxoplasma gondii
10.1046/j.1432-1327.2000.01749.x
Disruption of six novel genes from the left arm of chromosome XV of Saccharomyces cerevisiae and basic phenotypic analysis of the generated mutants
10.1002/(sici)1097-0061(19990115)15:1<73::aid-yea341>3.0.co;2-q
Efficient transcription obtained by a new procedure of the tRNA-like structure of turnip yellow mosaic virus by a template-dependent and specific viral RNA polymerase
10.1016/s0166-0934(96)02166-0
Efficient transcription obtained by a new procedure of the tRNA-like structure of turnip yellow mosaic virus by a template-dependent and specific viral RNA polymerase (vol 64, pg 181, 1997)
10.1016/s0166-0934(96)02249-5
Expression of the 69K movement protein of turnip yellow mosaic virus in insect cells
10.1006/viro.1996.0246
Gene expression from viral RNA genomes
10.1007/bf00039391
Vascular movement of plant viruses
10.1094/mpmi-9-0435
IN-VITRO TRANSCRIPTS OF TURNIP YELLOW MOSAIC-VIRUS ENCOMPASSING A LONG 3' EXTENSION OR PRODUCED FROM A FULL-LENGTH CDNA CLONE HARBORING A 2 KB-LONG PCR-AMPLIFIED SEGMENT ARE INFECTIOUS
10.1016/s0923-2516(06)80049-x
Entry and release of hepatitis C virus in polarized human hepatocytes.
10.1128/jvi.00478-17
An ecological approach to discover new bioactive extracts and products: the case of extremophile plants.
10.1111/jphp.12728
Identification of a New Benzimidazole Derivative as an Antiviral against Hepatitis C Virus.
10.1128/jvi.00404-16
Middle East respiratory syndrome coronavirus infection is inhibited by griffithsin.
10.1016/j.antiviral.2016.07.011
Theaflavins, polyphenols of black tea, inhibit entry of hepatitis C virus
10.1101/325126
Viral hepatitis in the Peruvian Amazon: Ethnomedical context and phytomedical resource.
10.1016/j.jep.2020.112735
Functional Carbon Quantum Dots as Medical Countermeasures to Human Coronavirus.
10.1021/acsami.9b15032
Dehydrojuncusol, a Natural Phenanthrene Compound Extracted from Juncus maritimus, Is a New Inhibitor of Hepatitis C Virus RNA Replication.
10.1128/jvi.02009-18
Theaflavins, polyphenols of black tea, inhibit entry of hepatitis C virus in cell culture.
10.1371/journal.pone.0198226
Correction for Belouzard et al., "Entry and Release of Hepatitis C Virus in Polarized Human Hepatocytes".
10.1128/jvi.00309-18
Plant extracts from Cameroonian medicinal plants strongly inhibit hepatitis C virus infection in vitro.
10.3389/fmicb.2015.00488
A yeast t-SNARE involved in endocytosis.
10.1091/mbc.9.10.2873
Large scale screening discovers clofoctol as an inhibitor of SARS-CoV-2 replication that reduces COVID-19-like pathology
10.1101/2021.06.30.450483
Priscille Brodin
Brodin Priscille
ORCID: 0000-0003-0991-7344
Email: priscille.brodin@inserm.fr
How can nanoparticles contribute to antituberculosis therapy?
10.1016/j.drudis.2017.01.011
Host-directed therapies offer novel opportunities for the fight against tuberculosis
10.1016/j.drudis.2017.05.005
A Bacterial Toxin with Analgesic Properties: Hyperpolarization of DRG Neurons by Mycolactone
10.3390/toxins9070227
A Bacterial Toxin with Analgesic Properties: Hyperpolarization of DRG Neurons by Mycolactone
10.3390/toxins9070227
10.3390/toxins9070227.
Clofazimine encapsulation in nanoporous silica particles for the oral treatment of antibiotic-resistant Mycobacterium tuberculosis infections
10.2217/nnm-2016-0364
Cyclodextrin-based nanocarriers containing a synergic drug combination: a potential formulation for pulmonary administration of antitubercular drugs
10.1016/j.ijpharm.2017.05.030
10.1016/j.ijpharm.2017.05.030.
Genome-wide, high-content siRNA screening identifies the Alzheimer's genetic risk factor FERMT2 as a major modulator of APP metabolism
10.1007/s00401-016-1652-z
Host-directed therapies offer novel opportunities for the fight against tuberculosis
10.1016/j.drudis.2017.05.005
10.1016/j.drudis.2017.05.005.
Identification of aminopyrimidine-sulfonamides as potent modulators of Wag31-mediated cell elongation in mycobacteria
10.1111/mmi.13535
Impact of pe_ pgrs33 Gene Polymorphisms on Mycobacterium tuberculosis Infection and Pathogenesis
10.3389/fcimb.2017.00137
LppM impact on the colonization of macrophages by Mycobacterium tuberculosis
10.1111/cmi.12619
Phenotypic assays for Mycobacterium tuberculosis infection
10.1002/cyto.a.23129
10.1002/cyto.a.23129.
Reversion of antibiotic resistance in Mycobacterium tuberculosis by spiroisoxazoline SMARt-420
10.1126/science.aag1006
A fragment merging approach towards the development of small molecule inhibitors of Mycobacterium tuberculosis EthR for use as ethionamide boosters
10.1039/c5ob02630j
Khaya grandifoliola C.DC: a potential source of active ingredients against hepatitis C virus in vitro
10.1007/s00705-016-2771-5
Mycobacterium tuberculosis LppM Displays an Original Structure and Domain Composition Linked to a Dual Localization
10.1016/j.str.2016.07.009
Mycolactone The amazing analgesic mycobacterial toxin
10.1051/medsci/20163202007
STAT3 Represses Nitric Oxide Synthesis in Human Macrophages upon Mycobacterium tuberculosis Infection
10.1038/srep29297
2-Carboxyquinoxalines Kill Mycobacterium tuberculosis through Noncovalent Inhibition of DprE1
10.1021/cb5007163
Cytosolic Access of Mycobacterium tuberculosis: Critical Impact of Phagosomal Acidification Control and Demonstration of Occurrence In Vivo
10.1371/journal.ppat.1004650
High content screening in chemical biology: overview and main challenges
10.1051/medsci/20153102016
High-Content Screening Technology Combined with a Human Granuloma Model as a New Approach To Evaluate the Activities of Drugs against Mycobacterium tuberculosis
10.1128/aac.03705-14
Increased protective efficacy of recombinant BCG strains expressing virulence-neutral proteins of the ESX-1 secretion system
10.1016/j.vaccine.2015.03.083
Plant extracts from Cameroonian medicinal plants strongly inhibit hepatitis C virus infection in vitro
10.3389/fmicb.2015.00438
Polyphenols Inhibit Hepatitis C Virus Entry by a New Mechanism of Action
10.1128/jvi.01473-15
Testing chemical and genetic Modulators in Mycobacterium tuberculosis infected cells using phenotypic assays
10.1007/978-1-4939-2450-9_24
A Microscopic Phenotypic Assay for the Quantification of Intracellular Mycobacteria Adapted for High-throughput/High-content Screening
10.3791/51114
Ligand Efficiency Driven Design of New Inhibitors of Mycobacterium tuberculosis Transcriptional Repressor EthR Using Fragment Growing, Merging, and Linking Approaches
10.1021/jm500422b
Mycobacterial Toxin Induces Analgesia in Buruli Ulcer by Targeting the Angiotensin Pathways
10.1016/j.cell.2014.04.040
Potent antiviral activity of Solanum rantonnetii and the isolated compounds against hepatitis C virus in vitro
10.1016/j.jff.2014.09.022
A novel specific edge effect correction method for RNA interference screenings
10.1093/bioinformatics/btr648
Discovery of Novel N-Phenylphenoxyacetamide Derivatives as EthR Inhibitors and Ethionamide Boosters by Combining High-Throughput Screening and Synthesis
10.1021/jm3003779
Ethionamide Boosters. 2. Combining Bioisosteric Replacement and Structure-Based Drug Design To Solve Pharmacokinetic Issues in a Series of Potent 1,2,4-Oxadiazole EthR Inhibitors
10.1021/jm200825u
The Balance of Apoptotic and Necrotic Cell Death in Mycobacterium tuberculosis Infected Macrophages Is Not Dependent on Bacterial Virulence
10.1371/journal.pone.0047573
Analogous Mechanisms of Resistance to Benzothiazinones and Dinitrobenzamides in Mycobacterium smegmatis
10.1371/journal.pone.0026675
Ethionamide Boosters: Synthesis, Biological Activity, and Structure-Activity Relationships of a Series of 1,2,4-Oxadiazole EthR Inhibitors
10.1021/jm200076a
High-content screening in infectious diseases
10.1016/j.cbpa.2011.05.023
Functional characterization of the Mycobacterium tuberculosis serine/threonine kinase PknJ
10.1099/mic.0.038133-0
High Content Phenotypic Cell-Based Visual Screen Identifies Mycobacterium tuberculosis Acyltrehalose-Containing Glycolipids Involved in Phagosome Remodeling
10.1371/journal.ppat.1001100
High-content imaging of Mycobacterium tuberculosis-infected macrophages: an in vitro model for tuberculosis drug discovery
10.4155/fmc.10.223
Long-circulating DNA lipid nanocapsules as new vector for passive tumor targeting
10.1016/j.biomaterials.2009.09.044
Automated High-Throughput siRNA Transfection in Raw 264.7 Macrophages: A Case Study for Optimization Procedure
10.1177/1087057108328762
Benzothiazinones Kill Mycobacterium tuberculosis by Blocking Arabinan Synthesis
10.1126/science.1171583
High Content Screening Identifies Decaprenyl-Phosphoribose 2 ' Epimerase as a Target for Intracellular Antimycobacterial Inhibitors
10.1371/journal.ppat.1000645
Systematic Genetic Nomenclature for Type VII Secretion Systems
10.1371/journal.ppat.1000507
Control of M-tuberculosis ESAT-6 secretion and specific T cell recognition by PhoP
10.1371/journal.ppat.0040033
Aquatic insects and transmission of Mycobacterium ulcerans
10.1051/medsci/20072367572
ESAT-6 from Mycobacterium tuberculosis dissociates from its putative chaperone CFP-10 under acidic conditions and exhibits membrane-lysing activity
10.1128/jb.00469-07
Impact of Mycobacterium ulcerans biofilm on transmissibility to ecological niches and Buruli ulcer pathogenesis
10.1371/journal.ppat.0030062
Protection against mycobacterium ulcerans lesion development by exposure to aquatic insect saliva
10.1371/journal.pmed.0040064
Support vector machines for automatic detection of tuberculosis bacteria in confocal microscopy images
10.1109/isbi.2007.356794
Synthesis and antimycobacterial evaluation of benzofurobenzopyran analogues
10.1016/j.bmc.2006.12.009
An increase in antimycobacterial Th1-cell responses by prime-boost protocols of immunization does not enhance protection against tuberculosis
10.1128/iai.74.4.2128-2137.2006
Benzofuro 3,2-f 1 benzopyrans: A new class of antitubercular agents
10.1016/j.bmc.2006.03.033
Dissection of ESAT-6 system 1 of Mycobacterium tuberculosis and impact on immunogenicity and virulence
10.1128/iai.74.1.88-98.2006
High frequency of CD4(+) T cells specific for the TB10.4 protein correlates with protection against Mycobacterium tuberculosis infection
10.1128/iai.02086-05
Inactivation of Rv2525c, a substrate of the twin arginine translocation (Tat) system of Mycobacterium tuberculosis, increases beta-lactam susceptibility and virulence
10.1128/jb.00631-06
Evaluation of vaccines in the EU TB vaccine cluster using a guinea pig aerosol infection model of tuberculosis
10.1016/j.tube.2004.09.009
Functional analysis of early secreted antigenic target-6, the dominant T-cell antigen of Mycobacterium tuberculosis, reveals key residues involved in secretion, complex formation, virulence, and immunogenicity
10.1074/jbc.M503515200
Immunogenic membrane-associated proteins of Mycobacterium tuberculosis revealed by proteomics
10.1099/mic.0.27799-0
Proteomic identification of M. tuberculosis protein kinase substrates: PknB recruits GarA, a FHA domain-containing protein, through activation loop-mediated interactions
10.1016/j.jmb.2005.05.049
Tuberculosis: from genome to vaccine
10.1586/14760584.4.4.541
Cell envelope protein PPE68 contributes to Mycobacterium tuberculosis RDI immunogenicity independently of a 10-kilodalton culture filtrate protein and ESAT-6
10.1128/iai.72.4.2170-2176.2004
Enhanced protection against tuberculosis by vaccination with recombinant Mycobacterium microti vaccine that induces T cell immunity against region of difference 1 antigens
10.1086/421468
ESAT-6 proteins: protective antigens and virulence factors?
10.1016/j.tim.2004.09.007
Macro-array and bioinformatic analyses reveal mycobacterial 'core' genes, variation in the ESAT-6 gene family and new phylogenetic markers for the Mycobacterium tuberculosis complex
10.1099/mic.0.26662-0
CD8(+)-T-cell responses of mycobacterium-infected mice to a newly identified major histocompatibility complex class I-restricted epitope shared by proteins of the ESAT-6 family
10.1128/iai.71.12.7173-7177.2003
Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis
10.1038/nm859
A new evolutionary scenario for the Mycobacterium tuberculosis complex
10.1073/pnas.052548299
Bacterial artificial chromosome-based comparative genomic analysis identifies Mycobacterium microti as a natural ESAT-6 deletion mutant
10.1128/iai.70.10.5568-5578.2002
Disruption of HIV-1 integrase-DNA complexes by short 6-oxocytosine-containing oligonucleotides
10.1021/bi015732y
Loss of RD1 contributed to the attenuation of the live tuberculosis vaccines Mycobacterium bovis BCG and Mycobacterium microti
10.1046/j.1365-2958.2002.03237.x
6-Oxocytidine containing oligonucleotides inhibit the HIV-1 integrase in vitro
10.1081/ncn-100002322
Determinants of Mg2+-dependent activities of recombinant human immunodeficiency virus type 1 integrase
10.1021/bi000398b
Inhibition of the human immunodeficiency virus type 1 DNA integration by modified oligonucleotides
10.1023/a:1026631910681
Branched oligonucleotide-intercalator conjugate forming a parallel stranded structure inhibits HIV-1 integrase
10.1016/s0014-5793(99)01350-2
Inhibition of HIV-1 integration by mono- & bi-functionalized triple helix forming oligonucleotides
10.1080/07328319908044831
Optimization of alternate-strand triple helix formation at the 5 '-TpA-3 ' and 5 '-ApT-3 ' junctions
10.1093/nar/27.15.3029
A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus
10.1074/jbc.272.25.16010
Mycobacterium tuberculosis inhibits human innate immune responses via the production of TLR2 antagonist glycolipids
10.1073/pnas.1707840114
ArfGAP1 restricts Mycobacterium tuberculosis entry by controlling the actin cytoskeleton
10.15252/embr.201744371
ArfGAP1 restricts Mycobacterium tuberculosis entry by controlling the actin cytoskeleton
10.15252/embr.201744371
10.15252/embr.201744371.
Combination therapy for tuberculosis treatment: pulmonary administration of ethionamide and booster co-loaded nanoparticles
10.1038/s41598-017-05453-3
Cyclipostins and Cyclophostin analogs as promising compounds in the fight against tuberculosis
10.1038/s41598-017-11843-4
10.1038/s41598-017-11843-4.
Fragment-Sized EthR Inhibitors Exhibit Exceptionally Strong Ethionamide Boosting Effect in Whole-Cell Mycobacterium tuberculosis Assays
10.1021/acschembio.7b00091
Host-pathogen systems for early drug discovery against tuberculosis
10.1016/j.mib.2017.11.017
10.1016/j.mib.2017.11.017.
Legionella pneumophila Modulates Mitochondrial Dynamics to Trigger Metabolic Repurposing of Infected Macrophages
10.1016/j.chom.2017.07.020
10.1016/j.chom.2017.07.020. Epub 2017 Aug 31.
Mycobacterium tuberculosis Controls Phagosomal Acidification by Targeting CISH-Mediated Signaling
10.1016/j.celrep.2017.08.101
10.1016/j.celrep.2017.08.101.
Mycobacterium tuberculosis inhibits human innate immune responses via the production of TLR2 antagonist glycolipids
10.1073/pnas.1707840114
10.1073/pnas.1707840114.
Identification of Piperazinylbenzenesulfonamides as New Inhibitors of Claudin-1 Trafficking and Hepatitis C Virus Entry
10.1128/jvi.01982-17
Multiplexed Quantitation of Intraphagocyte Mycobacterium tuberculosis Secreted Protein Effectors
10.1016/j.celrep.2018.03.125
Oxadiazolone derivatives, new promising multi-target inhibitors against M. tuberculosis
10.1016/j.bioorg.2018.08.025
Proteomics of Mycobacterium infection: Moving towards a Better Understanding of Pathogen-Driven immunomodulation
10.3389/fimmu.2018.00086
Synergy between circular bacteriocin AS-48 and ethambutol against Mycobacterium tuberculosis
10.1128/aac.00359-18
The EU approved antimalarial pyronaridine shows antitubercular activity and synergy with rifampicin, targeting RNA polymerase
10.1016/j.tube.2018.08.004
Cyclipostins and Cyclophostin analogs as promising compounds in the fight against tuberculosis
10.1038/s41598-017-11843-4
Cyclodextrin-based nanocarriers containing a synergic drug combination: A potential formulation for pulmonary administration of antitubercular drugs
10.1016/j.ijpharm.2017.05.030
Host-pathogen systems for early drug discovery against tuberculosis
10.1016/j.mib.2017.11.017
Legionella pneumophila Modulates Mitochondrial Dynamics to Trigger Metabolic Repurposing of Infected Macrophages
10.1016/j.chom.2017.07.020
Mycobacterium tuberculosis Controls Phagosomal Acidification by Targeting CISH-Mediated Signaling
10.1016/j.celrep.2017.08.101
Phenotypic assays for Mycobacterium tuberculosis infection
10.1002/cyto.a.23129
A fast, fully automated cell segmentation algorithm for high-throughput and high-content screening
10.1002/cyto.a.20627
Compartmentalized Encapsulation of Two Antibiotics in Porous Nanoparticles: an Efficient Strategy to Treat Intracellular Infections
10.1002/ppsc.201800360
Spatiotemporal Changes of the Phagosomal Proteome in Dendritic Cells in Response to LPS Stimulation
10.1074/mcp.RA119.001316
Mycolactone as Analgesic: Subcutaneous Bioavailability Parameters
10.3389/fphar.2019.00378
Intrinsic Antibacterial Activity of Nanoparticles Made of β-Cyclodextrins Potentiates Their Effect as Drug Nanocarriers against Tuberculosis
10.1021/acsnano.8b07902
Mitochondrial Dynamics and Activity in Legionella-Infected Cells
10.1007/978-1-4939-9048-1_13
Heparin-Binding Hemagglutinin Adhesin (HBHA) Is Involved in Intracytosolic Lipid Inclusions Formation in Mycobacteria
10.3389/fmicb.2018.02258
Dehydrojuncusol, a Natural Phenanthrene Compound Extracted from Juncus maritimus, Is a New Inhibitor of Hepatitis C Virus RNA Replication
10.1128/jvi.02009-18
A novel codrug made of the combination of ethionamide and its potentiating booster: synthesis, self-assembly into nanoparticles and antimycobacterial evaluation
10.1039/C9OB00680J
Could Mycolactone Inspire New Potent Analgesics? Perspectives and Pitfalls
10.3390/toxins11090516
Paradoxical Roles of the MAL/Tirap Adaptor in Pathologies.
10.3389/fimmu.2020.569127
Fragment-Based Optimized EthR Inhibitors with in Vivo Ethionamide Boosting Activity.
10.1021/acsinfecdis.9b00277
Intracellular and in vivo evaluation of imidazo[2,1-b]thiazole-5-carboxamide anti-tuberculosis compounds.
10.1371/journal.pone.0227224
Preclinical assessment of a new live attenuated Mycobacterium tuberculosis Beijing-based vaccine for tuberculosis.
10.1016/j.vaccine.2019.11.085
IRG1 controls immunometabolic host response and restricts intracellular Mycobacterium tuberculosis infection
10.1101/761551
Worms' Antimicrobial Peptides.
10.3390/md17090512
T(oo)bAd.
10.1038/s41589-019-0347-x
Theaflavins, polyphenols of black tea, inhibit entry of hepatitis C virus in cell culture.
10.1371/journal.pone.0198226
Plant extracts from Cameroonian medicinal plants strongly inhibit hepatitis C virus infection in vitro.
10.3389/fmicb.2015.00488
Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis.
10.1038/nm.3262
Discovery of novel N-phenylphenoxyacetamide derivatives as EthR inhibitors and ethionamide boosters by combining high-throughput screening and synthesis.
10.1021/jm300377g
Shortening the drug discovery pipeline: small molecule high content screening for lead discovery in neglected disease.
10.1186/1753-6561-5-s1-p38
Automated HTS/HCS for antivirals using visual HIV full replication assays.
10.1186/1742-4690-6-s2-p82
Influence of ESAT-6 secretion system 1 (RD1) of Mycobacterium tuberculosis on the interaction between mycobacteria and the host immune system.
10.4049/jimmunol.174.6.3570
Cell microbiology interview
10.1111/cmi.13288
Pathogenomic analyses of Mycobacterium microti, an ESX-1-deleted member of the Mycobacterium tuberculosis complex causing disease in various hosts
10.1099/mgen.0.000505
Céline Rivière
Rivière Céline
ORCID: 0000-0002-8618-5530
Neoboutonia melleri var velutina Prain: In vitro and in vivo hepatoprotective effects of the aqueous stem bark extract on acute hepatitis models
10.1186/s12906-018-2091-2
Potential antioxidant compounds in Mallotus species fingerprints. Part I: Indication, using linear multivariate calibration techniques
10.1016/j.aca.2009.07.020
Antimicrobial activity of selected Iranian medicinal plants against a broad spectrum of pathogenic and drug multiresistant micro-organisms
10.1111/lam.12294
Potential antioxidant compounds in Mallotus species fingerprints. Part II: Fingerprint alignment, data analysis and peak identification
10.1016/j.aca.2012.01.058
Anthocyanin identification and composition of wild Vitis spp. accessions by using LC-MS and LC-NMR
10.1016/j.aca.2011.11.060
Potential antioxidant compounds in Mallotus species fingerprints. Part I: Indication, using linear multivariate calibration techniques
10.1016/j.aca.2009.08.024
Antiproliferative and Antibacterial Activities of Cirsium scabrum from Tunisia
10.1155/2017/7247016
Anthocyanin phytochemical profiles and anti-oxidant activities of vitis candicans and vitis doaniana
10.1002/pca.2447
Development of HPLC fingerprints for Mallotus species extracts and evaluation of the peaks responsible for their antioxidant activity
10.1016/j.jpba.2009.06.016
Rosmarinic acid and its methyl ester as antimicrobial components of the hydromethanolic extract of Hyptis atrorubens Poit. (Lamiaceae)
10.1155/2013/604536
Multivariate data analysis to evaluate the fingerprint peaks responsible for the cytotoxic activity of Mallotus species
10.1016/j.jchromb.2012.10.001
Polyphenols isolated from antiradical extracts of Mallotus metcalfianus
10.1016/j.phytochem.2008.10.008
Chemotaxonomic interest of iridoids isolated from a Malagasy species: Perichlaena richardii
10.1016/j.bse.2011.07.016
Stilbenoid profiles of canes from Vitis and Muscadinia species
10.1021/jf303843z
Chemical Composition and Antimicrobial Activity of the Essential Oil from Aerial Parts and Roots of Eryngium barrelieri Boiss. and Eryngium glomeratum Lam. from Tunisia
10.1002/cbdv.201600136
Flavonoids, megastigmanes and other constituents from Ardisia incarnata
10.1016/j.bse.2015.07.014
Biocontrol activity of effusol from the extremophile plant, Juncus maritimus, against the wheat pathogen Zymoseptoria tritici
10.1007/s11356-017-9043-0
Antiproliferative effects of isopentenylated coumarins isolated from Phellolophium madagascariense Baker
10.1080/14786410500277787
Polyphenols from the stems of Morus alba and their inhibitory activity against nitric oxide production by lipopolysaccharide-activated microglia
10.1016/j.fitote.2014.06.001
N-methyl-5-carboxamide-2-pyridone from Mallotus barbatus: A chemosystematic marker of the Euphorbiaceae genus Mallotus
10.1016/j.bse.2012.05.004
An ecological approach to discover new bioactive extracts and products: the case of extremophile plants
10.1111/jphp.12728
Mallotus species from Vietnamese mountainous areas: Phytochemistry and pharmacological activities
10.1007/s11101-009-9152-6
Importance de l'identification botanique dans la démarche ethnopharmacologique; cas d'une Bignoniaceae malgache, Perichlaena richardii Baill
10.1080/12538078.2005.10515496
Dihydrochalcones: Occurrence in the Plant Kingdom, Chemistry and Biological Activities
10.1016/B978-0-444-63932-5.00007-3
Antimicrobial prenylated benzoylphloroglucinol derivatives and xanthones from the leaves of Garcinia goudotiana
10.1016/j.phytochem.2014.03.006
Natural stilbenoids: Distribution in the plant kingdom and chemotaxonomic interest in Vitaceae
10.1039/c2np20049j
Antispasmodic and antioxidant activities of fractions and bioactive constituent davidigenin isolated from Mascarenhasia arborescens
10.1016/j.jep.2010.05.017
Phenolic compounds from humulus lupulus as natural antimicrobial products: New weapons in the fight against methicillin resistant staphylococcus aureus, leishmania mexicana and trypanosoma brucei strains
10.3390/molecules24061024
Plant therapy in the Peruvian Amazon (Loreto) in case of infectious diseases and its antimicrobial evaluation
10.1016/j.jep.2019.112411
Humulus lupulus L., a very popular beer ingredient and medicinal plant: overview of its phytochemistry, its bioactivity, and its biotechnology
10.1007/s11101-018-9584-y
Antifungal activity of hop extracts and compounds against the wheat pathogen Zymoseptoria tritici
10.1016/j.indcrop.2018.05.061
Amaranthaceae halophytes from the French Flanders coast of the North Sea: a review of their phytochemistry and biological activities
10.1007/s11101-019-09636-w
Dehydrojuncusol, a natural phenanthrene compound extracted from Juncus maritimus, is a new inhibitor of hepatitis C virus RNA replication
10.1128/JVI.02009-18
Theaflavins, polyphenols of black tea, inhibit entry of hepatitis C virus in cell culture
10.1371/journal.pone.0198226
Trends in natural product research: PSE young scientists’ meeting Lille 2017: Natural products in health, agro-food and cosmetics
10.1007/s11101-018-9587-8
Effects of domestic cooking process on the chemical and biological properties of dietary phytochemicals
10.1016/j.tifs.2019.01.004
Dehydrojuncusol, a Natural Phenanthrene Compound Extracted from Juncus maritimus Is a New Inhibitor of Hepatitis C Virus Replication
10.1101/469361
MeJA Elicitation of Chicory Hairy Roots Promotes Efficient Increase of 3,5-diCQA Accumulation, a Potent Antioxidant and Antibacterial Molecule
10.3390/antibiotics9100659
Jean Dubuisson
Dubuisson Jean
ORCID: 0000-0003-1626-7693
Addressing the next challenges: A summary of the 22nd international symposium on hepatitis C virus and related viruses
10.1016/j.jhep.2015.12.021
Hepatitis C Virus Resistance to Carbohydrate-Binding Agents
10.1371/journal.pone.0149064
Identification of a new benzimidazole derivative as an antiviral against hepatitis C virus
10.1128/JVI.00404-16
Identification of class II ADP-ribosylation factors as cellular factors required for hepatitis C virus replication
10.1111/cmi.12572
Middle East respiratory syndrome coronavirus infection is inhibited by griffithsin
10.1016/j.antiviral.2016.07.011
Morphology and Molecular Composition of Purified Bovine Viral Diarrhea Virus Envelope
10.1371/journal.ppat.1005476
Study of hepatitis E virus infection of genotype 1 and 3 in mice with humanised liver
10.1136/gutjnl-2015-311109
Alphacoronaviruses Detected in French Bats Are Phylogeographically Linked to Coronaviruses of European Bats
10.3390/v7122937
Boronic acid-modified lipid nanocapsules: a novel platform for the highly efficient inhibition of hepatitis C viral entry
10.1039/c4nr03875d
Characterization of Hepatitis C Virus Interaction with Heparan Sulfate Proteoglycans
10.1128/JVI.03647-14
Claudin-6 and Occludin Natural Variants Found in a Patient Highly Exposed but Not Infected with Hepatitis C Virus (HCV) Do Not Confer HCV Resistance In Vitro
10.1371/journal.pone.0142539
HCV envelope glycoproteins in virion assembly and entry
10.2217/FVL.14.114
Hepatitis C Virus Envelope Glycoprotein E1 Forms Trimers at the Surface of the Virion
10.1128/JVI.00991-15
New Insights into the Understanding of Hepatitis C Virus Entry and Cell-to-Cell Transmission by Using the Ionophore Monensin A
10.1128/JVI.00192-15
Polyphenols Inhibit Hepatitis C Virus Entry by a New Mechanism of Action
10.1128/JVI.01473-15
Regulation of core expression during the hepatitis C virus life cycle
10.1099/vir.0.070433-0
A chimeric protein encompassing hepatitis C virus epitopes is able to elicit both humoral and cell-mediated immune responses in mice
10.1002/bab.1223
Analysis of Serine Codon Conservation Reveals Diverse Phenotypic Constraints on Hepatitis C Virus Glycoprotein Evolution
10.1128/JVI.01745-13
HCV-specific immune responses induced by CIGB-230 in combination with IFN-alpha plus ribavirin
10.3748/wjg.v20.i1.148
Hepatitis C Virus Capsid Protein and Intracellular Lipids Interplay and Its Association With Hepatic Steatosis
10.5812/hepatmon.17812
Hepatitis C virus life cycle and lipid metabolism
10.3390/biology3040892
Identification of a Novel Drug Lead That Inhibits HCV Infection and Cell-to-Cell Transmission by Targeting the HCV E2 Glycoprotein
10.1371/journal.pone.0111333
Identification of Conserved Residues in Hepatitis C Virus Envelope Glycoprotein E2 That Modulate Virus Dependence on CD81 and SRB1 Entry Factors
10.1128/JVI.01402-14
Incorporation of Hepatitis C Virus E1 and E2 Glycoproteins: The Keystones on a Peculiar Virion
10.3390/v6031149
Neutralizing antibodies and broad, functional T cell immune response following immunization with hepatitis C virus proteins-based vaccine formulation
10.1016/j.vaccine.2014.01.046
Successful Anti-Scavenger Receptor Class B Type I (SR-BI) Monoclonal Antibody Therapy in Humanized Mice After Challenge With HCV Variants With In Vitro Resistance to SR-BI-Targeting Agents
10.1002/hep.27196
Virology and cell biology of the hepatitis C virus life cycle - An update
10.1016/j.jhep.2014.06.031
Additional Glycosylation Within a Specific Hypervariable Region of Subtype 3a of Hepatitis C Virus Protects Against Virus Neutralization
10.1093/infdis/jit376
Disulfide Bonds in Hepatitis C Virus Glycoprotein E1 Control the Assembly and Entry Functions of E2 Glycoprotein
10.1128/JVI.02659-12
EWI-2wint promotes CD81 clustering that abrogates Hepatitis C Virus entry
10.1111/cmi.12112
Hepatitis C Virus Replication and Golgi Function in Brefeldin A-Resistant Hepatoma-Derived Cells
10.1371/journal.pone.0074491
Permissivity of Primary Human Hepatocytes and Different Hepatoma Cell Lines to Cell Culture Adapted Hepatitis C Virus
10.1371/journal.pone.0070809
Phenylboronic-Acid-Modified Nanoparticles: Potential Antiviral Therapeutics
10.1021/am403770q
Structural knowledge of HCV envelope protein region recognized by broadly neutralizing antibodies
10.2217/fvl.13.75
The Antimalarial Ferroquine Is An Inhibitor of Hepatitis C Virus
10.1002/hep.26273
Virus-neutralizing antibodies to hepatitis C virus
10.1111/jvh.12094
(-)-Epigallocatechin-3-gallate is a new inhibitor of hepatitis C virus entry
10.1002/hep.24803
Hepatitis C Virus and Natural Compounds: A New Antiviral Approach?
10.3390/v4102197
New advances in the molecular biology of hepatitis C virus infection: towards the identification of new treatment targets
10.1136/gutjnl-2012-302048
Role of low-density lipoprotein receptor in the hepatitis C virus life cycle
10.1002/hep.25501
Three Different Functional Microdomains in the Hepatitis C Virus Hypervariable Region 1 (HVR1) Mediate Entry and Immune Evasion
10.1074/jbc.M112.382341
Characterization of antibody-mediated neutralization directed against the hypervariable region 1 of hepatitis C virus E2 glycoprotein
10.1099/vir.0.028092-0
Comprehensive linker-scanning mutagenesis of the hepatitis C virus E1 and E2 envelope glycoproteins reveals new structure-function relationships
10.1099/vir.0.034314-0
Griffithsin Has Antiviral Activity against Hepatitis C Virus
10.1128/AAC.00633-11
HCV replication and assembly: a play in one act
10.2217/FVL.11.69
Hepatitis C Patient-Derived Glycoproteins Exhibit Marked Differences in Susceptibility to Serum Neutralizing Antibodies: Genetic Subtype Defines Antigenic but Not Neutralization Serotype
10.1128/JVI.01332-10
Hepatitis C Virus Assembly Imaging
10.3390/v3112238
Hepatitis C virus entry into the hepatocyte
10.2478/s11535-011-0076-y
Hepatocyte-derived cultured cells with unusual cytoplasmic keratin-rich spheroid bodies
10.1016/j.yexcr.2011.08.018
Identification of New Functional Regions in Hepatitis C Virus Envelope Glycoprotein E2
10.1128/JVI.02170-10
Interacting Regions of CD81 and Two of Its Partners, EWI-2 and EWI-2wint, and Their Effect on Hepatitis C Virus Infection
10.1074/jbc.M111.220103
NS2 Protein of Hepatitis C Virus Interacts with Structural and Non-Structural Proteins towards Virus Assembly
10.1371/journal.ppat.1001278
The Hepatitis C Virus Glycan Shield and Evasion of the Humoral Immune Response
10.3390/v3101909
Characterization of the Envelope Glycoproteins Associated with Infectious Hepatitis C Virus
10.1128/JVI.01180-10
Identification of a dominant endoplasmic reticulum-retention signal in yellow fever virus pre-membrane protein
10.1099/vir.0.015339-0
Identification of Basic Amino Acids at the N-Terminal End of the Core Protein That Are Crucial for Hepatitis C Virus Infectivity
10.1128/JVI.01393-10
Identification of GBF1 as a Cellular Factor Required for Hepatitis C Virus RNA Replication
10.1128/JVI.01190-09
Last Stop Before Exit - Hepatitis C Assembly and Release as Antiviral Drug Targets
10.3390/v2081782
NMR Structure and Ion Channel Activity of the p7 Protein from Hepatitis C Virus
10.1074/jbc.M110.122895
Recent Advances in Hepatitis C Virus Cell Entry
10.3390/v2030692
Role of lipid metabolism in hepatitis C virus assembly and entry
10.1042/BC20090125
Role of N-Linked Glycans in the Functions of Hepatitis C Virus Envelope Proteins Incorporated into Infectious Virions
10.1128/JVI.01548-10
Enhanced anti-HCV activity of interferon alpha 17 subtype
10.1186/1743-422X-6-70
Immunogenicity of CIGB-230, a therapeutic DNA vaccine preparation, in HCV-chronically infected individuals in a Phase I clinical trial
10.1111/j.1365-2893.2008.01058.x
N-glycans as contributors in the biological properties of the hepatitis C virus envelope proteins
10.1684/vir.2009.0270
Occludin, the final essential factor for HCV entry?
10.2217/FVL.09.13
Rapid synchronization of hepatitis C virus infection by magnetic adsorption
10.1016/j.jviromet.2008.11.015
The association of CD81 with tetraspanin-enriched microdomains is not essential for Hepatitis C virus entry
10.1186/1471-2180-9-111
Ceramide enrichment of the plasma membrane induces CD81 internalization and inhibits hepatitis C virus entry
10.1111/j.1462-5822.2007.01070.x
Early steps of the hepatitis C virus life cycle
10.1111/j.1462-5822.2007.01107.x
Hepatitis C virus (HCV)-induced immunoglobulin hypermutation reduces the affinity and neutralizing activities of antibodies against HCV envelope protein
10.1128/JVI.02582-07
Hepatitis C virus entry into host cells
10.1007/s00018-007-7291-8
Low levels of hepatitis C virus (HCV) neutralizing antibodies in patients coinfected with HCV and human immunodeficiency virus
10.1086/589777
Serum-derived hepatitis C virus infection of primary human hepatocytes is tetraspanin CD81 dependent
10.1128/JVI.01443-07
The CD81 Partner EWI-2wint Inhibits Hepatitis C Virus Entry
10.1371/journal.pone.0001866
CD81 expression is important for the permissiveness of Huh7 cell clones for heterogeneous hepatitis C virus infection
10.1128/JVI.01573-06
Hepatitis C virus proteins
10.3748/wjg.v13.i17.2406
Human combinatorial libraries yield rare antibodies that broadly neutralize hepatitis C virus
10.1073/pnas.0705522104
New pandemics: HIV and AIDS, HCV and chronic hepatitis, influenza virus and flu
10.1186/1742-4690-4-8
Reduction of the infectivity of hepatitis C virus pseudoparticles by incorporation of misfolded glycoproteins induced by glucosidase inhibitors
10.1099/vir.0.82465-0
Robust production of infectious viral particles in Huh-7 cells by introducing mutations in hepatitis C virus structural proteins
10.1099/vir.0.82872-0
The Alphavirus 6K protein activates endogenous ionic conductances when expressed in Xenopus oocytes
10.1007/s00232-007-9003-6
The neutralizing activity of anti-hepatitis C virus antibodies is modulated by specific glycans on the E2 envelope protein
10.1128/JVI.00127-07
Transmembrane domains of hepatitis C virus envelope glycoproteins: Residues involved in E1E2 heterodimerization and involvement of these domains in virus entry
10.1128/JVI.02198-06
Antiviral effect of alpha-glucosidase inhibitors on viral morphogenesis and binding properties of hepatitis C virus-like particles
10.1099/vir.0.81503-0
Cyanovirin-N inhibits hepatitis C virus entry by binding to envelope protein glycans
10.1074/jbc.M602431200
Hepatitis C virus entry depends on clathrin-mediated endocytosis
10.1128/JVI.00024-06
Hepatitis C virus entry: potential receptors and their biological functions
10.1099/vir.0.81646-0
High density lipoprotein inhibits hepatitis C virus-neutralizing antibodies by stimulating cell entry via activation of the scavenger receptor BI
10.1074/jbc.M602706200
High-density lipoproteins reduce the neutralizing effect of hepatitis C virus (HCV)-infected patient antibodies by promoting HCV entry
10.1099/vir.0.81932-0
Serum amyloid A has antiviral activity against hepatitis C virus by inhibiting virus entry in a cell culture system
10.1002/hep.21406
Subcellular localization of hepatitis C virus structural proteins in a cell culture system that efficiently replicates the virus
10.1128/JVI.80.6.2832-2841.2006
Analysis of a highly flexible conformational immunogenic domain a in hepatitis C virus E2
10.1128/JVI.79.21.13199-13208.2005
Analysis of the binding of hepatitis C virus genotype 1a and 1b E2 glycoproteins to peripheral blood mononuclear cell subsets
10.1099/vir.0.81169-0
Basic residues in hyervariable region 1 of hepatitis C virus envelope glycoprotein E2 contribute to virus entry
10.1128/JVI.79.24.15331-15341.2005
Bovine viral diarrhea virus entry is dependent on clathrin-mediated endocytosis
10.1128/JVI.79.16.10826-10829.2005
Characterization of host-range and cell entry properties of the major genotypes and subtypes of hepatitis C virus
10.1002/hep.20542
Contribution of the charged residues of hepatitis C virus glycoprotein E2 transmembrane domain to the functions of the E1E2 heterodimer
10.1099/vir.0.81140-0
High density lipoproteins facilitate hepatitis C virus entry through the scavenger receptor class B type I
10.1074/jbc.M411600200
Interactions between virus proteins and host cell membranes during the viral life cycle
10.1016/S0074-7696(05)45006-8
Role of N-linked glycans in the functions of hepatitis C virus envelope glycoproteins
10.1128/JVI.79.13.8400-8409.2005
Characterization of functional hepatitis C virus envelope glycoproteins
10.1128/JVI.78.6.2994-3002.2004
Functional hepatitis C virus envelope glycoproteins
10.1016/j.biolcel.2004.03.008
Hepatitis C virus E2 has three immunogenic domains containing conformational epitopes with distinct properties and biological functions
10.1128/JVI.78.17.9224-9232.2004
Incomplete humoral immunity against hepatitis C virus is linked with distinct recognition of putative multiple receptors by E2 envelope glycoprotein
10.4049/jimmunol.173.1.446
Positive effect of the hepatitis C virus nonstructural 5A protein on viral multiplication
10.1007/s00705-003-0291-6
Regulation of hepatitis C virus polyprotein processing by signal peptidase involves structural determinants at the p7 sequence junctions
10.1074/jbc.M406315200
Structural biology of hepatitis C virus
10.1002/hep.20032
The transmembrane domains of the prM and E proteins of yellow fever virus are endoplasmic reticulum localization signals
10.1128/JVI.78.22.12591-12602.2004
Another putative receptor for hepatitis C virus
10.1002/hep.510370327
CD81-dependent binding of hepatitis C virus E1E2 heterodimers
10.1128/JVI.77.19.10677-10683.2003
Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor
10.1074/jbc.M305289200
Characterization of the expression of the hepatitis C virus F protein
10.1099/vir.0.19065-0
Glycosylation of hepatitis C virus envelope proteins
10.1016/S0300-9084(03)00004-X
Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes
10.1084/jem.20021756
Role of the transmembrane domains of prM and E proteins in the formation of yellow fever virus envelope
10.1128/JVI.77.2.813-820.2003
Topology of hepatitis C virus envelope glycoproteins
10.1002/rmv.391
Binding of hepatitis C virus-like particles derived from infectious clone H77C to defined human cell lines
10.1128/JVI.76.3.1181-1193.2002
Glycosylation of the hepatitis C virus envelope protein E1 occurs posttranslationally in a mannosylphosphoryldolichol-deficient CHO mutant cell line
10.1093/glycob/12.2.95
Interaction of hepatitis C virus proteins with host cell membranes and lipids
10.1016/S0962-8924(02)02383-8
Live and killed rhabdovirus-based vectors as potential hepatitis C vaccines
10.1006/viro.2001.1212
Reconstitution of hepatitis C virus envelope glycoproteins into liposomes as a surrogate model to study virus attachment
10.1074/jbc.M111020200
Subcellular localization and topology of the p7 polypeptide of hepatitis C virus
10.1128/JVI.76.8.3720-3730.2002
Topological changes in the transmembrane domains of hepatitis C virus envelope glycoproteins
10.1093/emboj/cdf295
Biogenesis of hepatitis C virus envelope glycoproteins
10.1099/0022-1317-82-11-2589
Coexpression of hepatitis C virus envelope proteins E1 and E2 in cis improves the stability of membrane insertion of E2
10.1099/0022-1317-82-7-1629
Mimotopes of the hepatitis C virus hypervariable region 1, but not the natural sequences, induce cross-reactive antibody response by genetic immunization
10.1053/jhep.2001.22175
Nonenveloped nucleocapsids of hepatitis C virus in the serum of infected patients
10.1128/JVI.75.17.8240-8250.2001
Charged residues in the transmembrane domains of hepatitis C virus glycoproteins play a major role in the processing, subcellular localization, and assembly of these envelope proteins
10.1128/JVI.74.8.3623-3633.2000
Construction and characterization of chimeric hepatitis C virus E2 glycoproteins: analysis of regions critical for glycoprotein aggregation and CD81 binding
10.1099/0022-1317-81-12-2873
Functional characterization of intracellular and secreted forms of a truncated hepatitis C virus E2 glycoprotein
10.1128/JVI.74.2.702-709.2000
Glycosylation of the hepatitis C virus envelope protein E1 is dependent on the presence of a downstream sequence on the viral polyprotein
10.1074/jbc.M004326200
Reciprocal relationship between alpha 1,2 mannosidase processing and reglucosylation in the rough endoplasmic reticulum of Man-P-Dol deficient cells
10.1046/j.1432-1327.2000.01111.x
The transmembrane domains of hepatitis C virus envelope glycoproteins E1 and E2 play a major role in heterodimerization
10.1074/jbc.M003003200
Analysis of the glycosylation sites of hepatitis C virus (HCV) glycoprotein E1 and the influence of E1 glycans on the formation of the HCV glycoprotein complex
10.1099/0022-1317-80-4-887
Characterization of aggregates of hepatitis C virus glycoproteins
10.1099/0022-1317-80-12-3099
Retention and degradation of N-glycoproteins in the rough endoplasmic reticulum
10.1023/A:1020228725997
Characterization of human monoclonal antibodies specific to the hepatitis C virus glycoprotein E2 with in vitro binding neutralization properties
10.1006/viro.1998.9202
Hepatitis C virus glycoprotein complex localization in the endoplasmic reticulum involves a determinant for retention and not retrieval
10.1074/jbc.273.48.32088
Characterization of truncated forms of hepatitis C virus glycoproteins
10.1099/0022-1317-78-9-2299
SYNTHESIS AND PROCESSING OF BOVINE HERPESVIRUS-1 GLYCOPROTEIN-H
10.1016/S0042-6822(95)80083-2
ATTACHMENT OF THE GAMMAHERPESVIRUS BOVINE HERPESVIRUS-4 IS MEDIATED BY THE INTERACTION OF GP8 GLYCOPROTEIN WITH HEPARIN-LIKE MOIETIES ON THE CELL-SURFACE
10.1006/viro.1993.1471
IDENTIFICATION OF 108-K, 93-K, AND 42-K GLYCOPROTEINS OF BOVINE HERPESVIRUS-1 BY MONOCLONAL-ANTIBODIES
10.1007/BF01309747
EPIDEMIOLOGIC EVALUATION OF A MONOCLONAL ELISA DETECTING BOVINE VIRAL DIARRHEA PESTIVIRUS ANTIGENS IN FIELD BLOOD-SAMPLES OF PERSISTENTLY INFECTED CATTLE
10.1016/0166-0934(92)90010-B
IDENTIFICATION AND CHARACTERIZATION OF GLYCOPROTEIN-GP1 OF BOVINE HERPESVIRUS TYPE-4
10.1099/0022-1317-73-5-1293
MECHANISMS OF BOVINE HERPESVIRUS TYPE-1 NEUTRALIZATION BY MONOCLONAL-ANTIBODIES TO GLYCOPROTEIN-GI, GLYCOPROTEIN-GIII AND GLYCOPROTEIN-GIV
10.1099/0022-1317-73-8-2031
MOLECULAR-BIOLOGY OF BOVINE HERPESVIRUS TYPE-4
10.1016/0378-1135(92)90037-T
PROTEINS OF BOVINE HERPESVIRUS TYPE-4 RELEASED INTO THE CULTURE-MEDIUM OF PRODUCTIVELY INFECTED-CELLS - IDENTIFICATION OF A 135K GLYCOPROTEIN INVOLVED IN VIRAL ATTACHMENT
10.1099/0022-1317-73-1-189
A MONOCLONAL ELISA FOR BOVINE VIRAL DIARRHEA PESTIVIRUS ANTIGEN-DETECTION IN PERSISTENTLY INFECTED CATTLE
10.1016/0166-0934(91)90133-K
ANTIGENIC AND GENOMIC IDENTITY BETWEEN SIMIAN HERPESVIRUS AOTUS TYPE-2 AND BOVINE HERPESVIRUS TYPE-4
10.1099/0022-1317-72-3-715
BOVINE HERPESVIRUS-4 ISOLATES - A COMPARISON OF 3 MAJOR GLYCOPROTEINS
10.1016/0378-1135(91)90132-Y
CHARACTERIZATION OF MONOCLONAL-ANTIBODIES TO BOVINE VIRAL DIARRHEA VIRUS - EVIDENCE OF A NEUTRALIZING ACTIVITY AGAINST GP48 IN THE PRESENCE OF GOAT ANTI-MOUSE IMMUNOGLOBULIN SERUM
10.1099/0022-1317-72-5-1195
COMPARISON OF PROTEINS OF SIMIAN HERPESVIRUS AOTUS TYPE-2 AND BOVINE HERPESVIRUS TYPE-4
10.1099/0022-1317-72-5-1145
FAILURE TO INFECT CATS WITH BOVINE HERPESVIRUS TYPE-4 STRAIN MOVAR 33/63
10.1136/vr.128.26.614
GENOMIC DIVERSITY AMONG BOVINE HERPESVIRUS-4 FIELD ISOLATES
10.1007/BF01319227
TEMPORAL CONTROL OF BOVINE HERPESVIRUS TYPE-4 GLYCOPROTEIN-SYNTHESIS
10.1099/0022-1317-72-6-1429
Bovine herpesvirus 4 genome: cloning, mapping and strain variation analysis
10.1099/0022-1317-71-1-133
Neutralization of bovine herpesvirus type 4 by pairs of monoclonal antibodies raised against two glycoproteins and identification of antigenic determinants involved in neutralization
10.1099/0022-1317-71-3-647
EXPERIMENTAL-INFECTION OF BULLS WITH A GENITAL ISOLATE OF BOVINE HERPESVIRUS-4 AND REACTIVATION OF LATENT VIRUS WITH DEXAMETHASONE
10.1016/0378-1135(89)90022-9
PRODUCTION AND CHARACTERIZATION OF MONOCLONAL-ANTIBODIES TO BOVID HERPESVIRUS-4
10.1016/0378-1135(89)90096-5
PROTEINS SPECIFIED BY BOVINE HERPESVIRUS TYPE-4 - STRUCTURAL PROTEINS OF THE VIRION AND IDENTIFICATION OF 2 MAJOR GLYCOPROTEINS BY USING MONOCLONAL-ANTIBODIES
10.1099/0022-1317-70-7-1743
BIOLOGICAL AND BIOCHEMICAL-COMPARISON OF BOVID HERPESVIRUS-4 STRAINS
10.1016/0378-1135(88)90015-6
Identification of Novel Functions for Hepatitis C Virus Envelope Glycoprotein E1 in Virus Entry and Assembly
10.1128/JVI.00048-17
Lettuce-produced hepatitis C virus E1E2 heterodimer triggers immune responses in mice and antibody production after oral vaccination
10.1111/pbi.12743
Interplay between hepatitis C virus and lipid metabolism during virus entry and assembly
10.1016/j.biochi.2017.06.009
Novel replicons and trans-encapsidation systems for Hepatitis C Virus proteins live imaging and virus-host interaction proteomics
10.1016/j.jviromet.2017.04.009
Entry and Release of Hepatitis C Virus in Polarized Human Hepatocytes
10.1128/JVI.00478-17
Claudin-1, miR-122 and apolipoprotein E transductions improve the permissivity of SNU-182, SNU-398 and SNU-449 hepatoma cells to hepatitis C virus
10.1111/jvh.12767
Development and characterization of a human monoclonal antibody targeting the N-terminal region of hepatitis C virus envelope glycoprotein E1
10.1016/j.virol.2017.10.019
Hepatitis E Virus Lifecycle and Identification of 3 Forms of the ORF2 Capsid Protein
10.1053/j.gastro.2017.09.020
Identification of GBF1 as a cellular factor required for hepatitis E virus RNA replication
10.1111/cmi.12804
Secretion of Hepatitis C Virus Replication Intermediates Reduces Activation of Toll Like Receptor 3 in Hepatocytes
10.1053/j.gastro.2018.03.020
Health-Related Quality of Life in Chronic HCV-Infected Patients Switching to Pegylated-Interferon-Free Regimens (ANRS CO20 CUPIC Cohort Study and SIRIUS Trial)
10.1007/s40271-017-0232-1
Impact of IL28B, APOH and ITPA Polymorphisms on Efficacy and Safety of TVR- or BOC-Based Triple Therapy in Treatment-Experienced HCV-1 Patients with Compensated Cirrhosis from the ANRS CO20-CUPIC Study
10.1371/journal.pone.0145105
The CUPIC algorithm: an accurate model for the prediction of sustained viral response under telaprevir or boceprevir triple therapy in cirrhotic patients
10.1111/jvh.12433
Functional Study of the C-Terminal Part of the Hepatitis C Virus E1 Ectodomain
10.1128/JVI.00939-18
HCoV-229E spike protein fusion activation by trypsin-like serine proteases is mediated by proteolytic processing in the S2 ' region
10.1099/jgv.0.001074
Identification of Piperazinylbenzenesulfonamides as New Inhibitors of Claudin-1 Trafficking and Hepatitis C Virus Entry
10.1128/jvi.01982-17
Investigation of the role of GBF1 in the replication of positive-sense single-stranded RNA viruses
10.1099/jgv.0.001099
Glycan Shielding and Modulation of Hepatitis C Virus Neutralizing Antibodies
10.3389/fimmu.2018.00910
Dehydrojuncusol, a Natural Phenanthrene Compound Extracted from Juncus maritimus Is a New Inhibitor of Hepatitis C Virus Replication
10.1101/469361
Functional and Physical Interaction between the Arf Activator GBF1 and Hepatitis C Virus NS3 Protein
10.1128/JVI.01459-18
Dehydrojuncusol, a Natural Phenanthrene Compound Extracted from Juncus maritimus , Is a New Inhibitor of Hepatitis C Virus RNA Replication
10.1128/JVI.02009-18
Toll-like receptor 5 agonist flagellin reduces influenza A virus replication independently of type I interferon and interleukin 22 and improves antiviral efficacy of oseltamivir
10.1016/j.antiviral.2019.05.002
New insights into the ORF2 capsid protein, a key player of the hepatitis E virus lifecycle
10.1038/s41598-019-42737-2
Le virus de l’hépatite E
10.1051/medsci/2018299
Theaflavins, polyphenols of black tea, inhibit entry of hepatitis C virus in cell culture
10.1371/journal.pone.0198226
Function of the HCV E1 envelope glycoprotein in viral entry and assembly
10.2217/fvl-2018-0180
Similarities and Differences Between HCV Pseudoparticle (HCVpp) and Cell Culture HCV (HCVcc) in the Study of HCV
10.1007/978-1-4939-8976-8_2
Use of whole-genome sequencing in the molecular investigation of care-associated HCoV-OC43 infections in a hematopoietic stem cell transplant unit
10.1016/j.jcv.2019.104206
A multiepitope peptide vaccine against HCV stimulates neutralizing humoral and persistent cellular responses in mice
10.1186/s12879-019-4571-5
Hepatitis C Virus Improves Human Tregs Suppressive Function and Promotes Their Recruitment to the Liver
10.3390/cells8101296
Functional Carbon Quantum Dots as Medical Countermeasures to Human Coronavirus
10.1021/acsami.9b15032
The C-terminal domain of the MERS coronavirus M protein contains a trans-Golgi network localization signal
10.1074/jbc.ra119.008964
Role of the cytosolic domain of occludin in trafficking and hepatitis C virus infection
10.1111/tra.12680
Safety and Efficacy of Avaren-Fc Lectibody Targeting HCV High-Mannose Glycans in a Human Liver Chimeric Mouse Model
10.1101/2020.04.22.056754
Anti-Spike, anti-Nucleocapsid and neutralizing antibodies in SARS-CoV-2 inpatients and asymptomatic carriers
10.1101/2020.05.12.20098236
Les coronavirus, ennemis incertains
10.1051/medsci/2020113
Viral hepatitis in the Peruvian Amazon: Ethnomedical context and phytomedical resource
10.1016/j.jep.2020.112735
Comparative Analysis of Hepatitis C Virus NS5A Dynamics and Localization in Assembly-Deficient Mutants
10.3390/pathogens10020172
Fluoxetine Can Inhibit SARS-CoV-2 In Vitro
10.3390/microorganisms9020339
Rapid Generation of Coronaviral Immunity Using Recombinant Peptide Modified Nanodiamonds
10.3390/pathogens10070861
Secretory Vesicles Are the Principal Means of SARS-CoV-2 Egress
10.3390/cells10082047
